UBS analyst Matthew Weston maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of £115.00. The company’s shares opened today at p11,364.00.

In a report released today, Peter Welford from Jefferies maintained a Hold rating on AstraZeneca (AZN – Research Report), with a price target of £109.00. The company’s shares opened today at ...

LONDON — Pharmaceutical company AstraZeneca on Friday cancelled a planned 450 million-pound ($560 million) investment in a vaccine manufacturing plant in northwest England, blaming the new ...

The positive recommendation from NICE for osimertinib was based on results from the ADAURA Phase III trial. In which, adjuvant treatment (after surgery) with osimertinib in patients with stage II ...

AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising ...

Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...

In substance and timing, AstraZeneca's decision to cancel a planned expansion of its flu vaccine facility at Speke is a blow to the government's recent zeal for growth. Instead of injecting £450m ...

FDA approves AstraZeneca's Datroway, reducing breast cancer progression risk by 37% per TROPION-Breast01 trial results. Datroway's safety profile remains consistent, with 4.2% ILD rate ...

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...

AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), in patients with a certain type of breast cancer. The drug, developed ...

AstraZeneca has abandoned a £450m investment in a major UK vaccine plant just days after Rachel Reeves vowed to “kick-start economic growth”. The drugmaker, which is Britain’s most valuable ...

AstraZeneca has pulled out of plans to build a new £450m facility in Liverpool. AstraZeneca, which produced one of the Covid-19 jabs, has an existing site on Renaissance Way, Speke and during the ...